Match!
Charles Theillet
French Institute of Health and Medical Research
162Publications
56H-index
9,407Citations
Publications 162
Newest
#1Yahya Ashraf (French Institute of Health and Medical Research)H-Index: 2
#2Hanane Mansouri (French Institute of Health and Medical Research)
Last.Henri-Alexandre Michaud (French Institute of Health and Medical Research)H-Index: 1
view all 37 authors...
Background Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The aspartic protease cathepsin D (cath-D), a marker of poor prognosis in breast cancer (BC), is overproduced and hypersecreted by human BC cells. This study explores whether cath-D is a tumor cell-associated ext...
#1Claire Fonti (University of Montpellier)H-Index: 1
#2Anne Saumet (University of Montpellier)H-Index: 9
Last.William Jacot (ICM Partners)H-Index: 20
view all 14 authors...
#1Laura Bourillon (French Institute of Health and Medical Research)
#2C. Bourgier (French Institute of Health and Medical Research)H-Index: 25
Last.Charline Ogier (French Institute of Health and Medical Research)H-Index: 1
view all 17 authors...
#1Elodie ChartronH-Index: 1
#2Charles Theillet (University of Montpellier)H-Index: 56
Last.William Jacot (University of Montpellier)H-Index: 20
view all 4 authors...
Abstract Mutation or epigenetic silencing of homologous recombination (HR) repair genes is characteristic of a growing proportion of triple-negative breast cancers (TNBCs) and high-grade serous ovarian carcinomas. Defects in HR lead to genome instability, allowing cells to acquire the multiple genetic alterations essential for cancer development. However, this deficiency can also be exploited by using DNA damaging agents or by targeting compensatory repair pathways. A noteworthy example is treat...
#1Stan P. du manoir (University of Montpellier)
#2Claire Fonti (University of Montpellier)H-Index: 1
Last.Michael Weber (UDS: University of Strasbourg)H-Index: 25
view all 11 authors...
Gene expression differences, combined with distinct patterns of genomic rearrangements and epigenetic modifications constitute the bases of molecular classification of breast cancer. Molecular subtypes may originate from different cell lineages in the mammary gland, but also from the early activation of oncogenes that may drive the establishment of these molecular subtypes. However, in the natural history of human cancer, it is difficult to discriminate between these two factors : cell lineage a...
#1Claire Fonti (French Institute of Health and Medical Research)
#2Anne Saumet (French Institute of Health and Medical Research)H-Index: 2
Last.William Jacot (ICM Partners)H-Index: 10
view all 14 authors...
Gene expression differences, combined with distinct patterns of genomic rearrangements and epigenetic modifications, have laid the bases of molecular classification of breast cancer. Different molecular subtypes are thought to originate from different cell lineages in the mammary gland, but the early activation of an oncogene could also play a role. It is, however, difficult to discriminate the respective inputs of oncogene activation or cell type of origin in the natural history of the tumor. I...
#1Caroline Kreuzinger (Medical University of Vienna)H-Index: 4
#2Angelika Geroldinger (Medical University of Vienna)H-Index: 6
Last.Ignace Vergote (Katholieke Universiteit Leuven)H-Index: 87
view all 22 authors...
Purpose: Most high grade serous ovarian cancer (HGSOC) patients develop recurrent disease after first line treatment, frequently with fatal outcome. This work aims at studying the molecular biology of both primary and recurrent HGSOC. Experimental design: Gene expression profiles of matched primary and recurrent fresh frozen tumor tissues from 66 HGSOC patients were obtained by RNA sequencing. Clustering analyses and pairwise comparison of the profiles between matched samples and subsequent func...
#1Eva ObermayrH-Index: 7
Last.Jalid SehouliH-Index: 52
view all 14 authors...
// Eva Obermayr 1 , Natalia Bednarz-Knoll 2 , Beatrice Orsetti 3, 4 , Heinz-Ulrich Weier 5 , Sandrina Lambrechts 6 , Dan Cacsire Castillo-Tong 1 , Alexander Reinthaller 1 , Elena Ioana Braicu 7 , Sven Mahner 8, 10 , Jalid Sehouli 7 , Ignace Vergote 6 , Charles Theillet 3, 4 , Robert Zeillinger 1, * and Burkhard Brandt 9, * 1 Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria 2 Institute of Tumor Biology, University Medical Center Eppendorf, Hamburg, Germany 3 ...
#1W. A. da Silveira (USP: University of São Paulo)H-Index: 1
#2Patricia Vianna Bonini Palma (NIST: National Institute of Standards and Technology)H-Index: 7
Last.Silvia Regina Rogatto (University of Southern Denmark)H-Index: 20
view all 13 authors...
Breast cancer is the most common cancer in women worldwide and metastatic dissemination is the principal factor related to death by this disease. Breast cancer stem cells (bCSC) are thought to be responsible for metastasis and chemoresistance. In this study, based on whole transcriptome analysis from putative bCSC and reverse engineering of transcription control networks, we identified two networks associated with this phenotype. One controlled by SNAI2, TWIST1, BNC2, PRRX1 and TBX5 drives a mes...
12345678910